Logo image of DTIL

PRECISION BIOSCIENCES INC (DTIL) Stock Overview

NASDAQ:DTIL - US74019P2074 - Common Stock

4.9 USD
-0.12 (-2.39%)
Last: 8/29/2025, 8:17:31 PM
4.91 USD
+0.01 (+0.2%)
After Hours: 8/22/2025, 8:03:53 PM

DTIL Key Statistics, Chart & Performance

Key Statistics
52 Week High11.09
52 Week Low3.61
Market Cap57.77M
Shares11.79M
Float10.42M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-8.81
PEN/A
Fwd PEN/A
Earnings (Next)11-03 2025-11-03/bmo
IPO03-28 2019-03-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


DTIL short term performance overview.The bars show the price performance of DTIL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5

DTIL long term performance overview.The bars show the price performance of DTIL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of DTIL is 4.9 USD. In the past month the price increased by 6.06%. In the past year, price decreased by -54.96%.

PRECISION BIOSCIENCES INC / DTIL Daily stock chart

DTIL Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About DTIL

Company Profile

DTIL logo image Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. The company is headquartered in Durham, North Carolina and currently employs 108 full-time employees. The company went IPO on 2019-03-28. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The firm's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The firm's iECURE-OTC program is developed in partnership with iECURE, Inc.

Company Info

PRECISION BIOSCIENCES INC

302 E Pettigrew St Ste A100

Durham NORTH CAROLINA 27701 US

CEO: Matthew Kane

Employees: 108

DTIL Company Website

DTIL Investor Relations

Phone: 19193145512

PRECISION BIOSCIENCES INC / DTIL FAQ

What is the stock price of PRECISION BIOSCIENCES INC today?

The current stock price of DTIL is 4.9 USD. The price decreased by -2.39% in the last trading session.


What is the ticker symbol for PRECISION BIOSCIENCES INC stock?

The exchange symbol of PRECISION BIOSCIENCES INC is DTIL and it is listed on the Nasdaq exchange.


On which exchange is DTIL stock listed?

DTIL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PRECISION BIOSCIENCES INC stock?

10 analysts have analysed DTIL and the average price target is 31.11 USD. This implies a price increase of 534.9% is expected in the next year compared to the current price of 4.9. Check the PRECISION BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PRECISION BIOSCIENCES INC worth?

PRECISION BIOSCIENCES INC (DTIL) has a market capitalization of 57.77M USD. This makes DTIL a Micro Cap stock.


How many employees does PRECISION BIOSCIENCES INC have?

PRECISION BIOSCIENCES INC (DTIL) currently has 108 employees.


What are the support and resistance levels for PRECISION BIOSCIENCES INC (DTIL) stock?

PRECISION BIOSCIENCES INC (DTIL) has a support level at 4.46 and a resistance level at 4.9. Check the full technical report for a detailed analysis of DTIL support and resistance levels.


Is PRECISION BIOSCIENCES INC (DTIL) expected to grow?

The Revenue of PRECISION BIOSCIENCES INC (DTIL) is expected to decline by -85.06% in the next year. Check the estimates tab for more information on the DTIL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PRECISION BIOSCIENCES INC (DTIL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PRECISION BIOSCIENCES INC (DTIL) stock pay dividends?

DTIL does not pay a dividend.


When does PRECISION BIOSCIENCES INC (DTIL) report earnings?

PRECISION BIOSCIENCES INC (DTIL) will report earnings on 2025-11-03, before the market open.


What is the Price/Earnings (PE) ratio of PRECISION BIOSCIENCES INC (DTIL)?

PRECISION BIOSCIENCES INC (DTIL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.81).


What is the Short Interest ratio of PRECISION BIOSCIENCES INC (DTIL) stock?

The outstanding short interest for PRECISION BIOSCIENCES INC (DTIL) is 13.06% of its float. Check the ownership tab for more information on the DTIL short interest.


DTIL Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to DTIL. When comparing the yearly performance of all stocks, DTIL is a bad performer in the overall market: 92.08% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DTIL Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to DTIL. DTIL has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DTIL Financial Highlights

Over the last trailing twelve months DTIL reported a non-GAAP Earnings per Share(EPS) of -8.81. The EPS decreased by -378.8% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -71.84%
ROE -229.8%
Debt/Equity 0.66
Chartmill High Growth Momentum
EPS Q2Q%-145.61%
Sales Q2Q%-99.96%
EPS 1Y (TTM)-378.8%
Revenue 1Y (TTM)-98.56%

DTIL Forecast & Estimates

10 analysts have analysed DTIL and the average price target is 31.11 USD. This implies a price increase of 534.9% is expected in the next year compared to the current price of 4.9.

For the next year, analysts expect an EPS growth of -3429.2% and a revenue growth -85.06% for DTIL


Analysts
Analysts84
Price Target31.11 (534.9%)
EPS Next Y-3429.2%
Revenue Next Year-85.06%

DTIL Ownership

Ownership
Inst Owners42.34%
Ins Owners8.54%
Short Float %13.06%
Short Ratio3.91